{
  "source": "PA-Notification-Turalio.txt",
  "chunks": [
    "UnitedHealthcare Pharmacy\nClinical Pharmacy Programs\nProgram Number 2024 P 1295-6\nProgram Prior Authorization/Notification\nMedication Turalio® (pexidartinib)\nP&T Approval Date 10/2019, 10/2020, 10/2021, 10/2022, 10/2023, 10/2024\nEffective Date 1/1/2025\n1. Background:\nTuralio (pexidartinib) is a kinase inhibitor indicated for the treatment of adult patients with\nsymptomatic tenosynovial giant cell tumor (TGCT) associated with severe morbidity or\nfunctional limitations and not amenable to improvement with surgery.\nThe National Cancer Comprehensive Network (NCCN) recommends Turalio as single-agent\ntherapy for the treatment of TGCT/ pigmented villonodular synovitis (PVNS) in patients\nwithout respect to morbidity and surgery eligibility. NCCN also recommends Turalio for\ncolony stimulating factor 1 receptor (CSF1R) mutation positive histiocytic neoplasms.\nCoverage Information:\nMembers will be required to meet the criteria below for coverage. For members under the age\nof 19 years, the prescription will automatically process without a coverage review.\nSome states mandate benefit coverage for off-label use of medications for some diagnoses or\nunder some circumstances. Some states also mandate usage of other Compendium references.\nWhere such mandates apply, they supersede language in the benefit document or in the\nnotification criteria.\n2. Coverage Criteriaa:\nA. Patients less than 19 years of age\n1. Turalio will be approved based on the following criterion:\na. Patient is less than 19 years of age\nAuthorization will be issued for 12 months.\nB. Tenosynovial Giant Cell Tumor/Pigmented Villonodular Synovitis\n1. Initial Authorization\na. Turalio will be approved based on the following criterion:\n(1) Diagnosis of tenosynovial giant cell tumor (TGCT)/ pigmented villonodular\nsynovitis (PVNS)\nAuthorization will be issued for 12 months.\n© 2024 UnitedHealthcare Services, Inc.\n1\n2. Reauthorization\na. Turalio will be approved based on the following criterion:\n(1) Patient does not show evid",
    "NS)\nAuthorization will be issued for 12 months.\n© 2024 UnitedHealthcare Services, Inc.\n1\n2. Reauthorization\na. Turalio will be approved based on the following criterion:\n(1) Patient does not show evidence of progressive disease while on Turalio therapy\nAuthorization will be issued for 12 months.\nC. Histiocytic Neoplasms\n1. Initial Authorization\na. Turalio will be approved based on all the following criteria:\n(1) Dignosis of one of the following:\n(a) Langerhans Cell Histiocytosis\n(b) Erdheim-Chester Disease\n(c) Rosai-Dorfman Disease\n-AND-\n(2) Colony stimulating factor 1 receptor (CSF1R) mutation positive\nAuthorization will be issued for 12 months.\n2. Reauthorization\na. Turalio will be approved based on the following criterion:\n(1) Patient does not show evidence of progressive disease while on Turalio therapy\nAuthorization will be issued for 12 months.\nD. NCCN Recommended Regimens\nThe drug has been recognized for treatment of the cancer indication by The National\nComprehensive Cancer Network (NCCN) Drugs and Biologics Compendium with a\nCategory of Evidence and Consensus of 1, 2A, or 2B\nAuthorization will be issued for 12 months.\na State mandates may apply. Any federal regulatory requirements and the member specific\nbenefit plan coverage may also impact coverage criteria. Other policies and utilization\nmanagement programs may apply.\n© 2024 UnitedHealthcare Services, Inc.\n2\n3. Additional Clinical Rules:\n• Notwithstanding Coverage Criteria, UnitedHealthcare may approve initial and re-\nauthorization based solely on previous claim/medication history, diagnosis codes (ICD-10)\nand/or claim logic. Use of automated approval and re-approval processes varies by program\nand/or therapeutic class.\n• Supply limits may be in place.\n4. References:\n1. Turalio [package insert]. Basking Ridge, NJ: Daiichi Sankyo, Inc. November 2023.\n2. The NCCN Drugs and Biologics Compendium (NCCN Compendium™). Available at\nhttps://www.nccn.org. Accessed August 28, 2024.\nProgram Prior Authorization/Notif",
    "e, NJ: Daiichi Sankyo, Inc. November 2023.\n2. The NCCN Drugs and Biologics Compendium (NCCN Compendium™). Available at\nhttps://www.nccn.org. Accessed August 28, 2024.\nProgram Prior Authorization/Notification - Turalio® (pexidartinib)\nChange Control\n10/2019 New program.\n10/2020 Annual review. Added PVNS to TGCT to coincide with NCCN\nreferencing. Updated background. Updated references.\n10/2021 Annual review. Clinical coverage criteria added per NCCN\nrecommendations for CSF1R mutation positive histiocytic neoplasms.\nBackground and reference updated.\n10/2022 Annual review with no change to clinical coverage criteria. Updated\nreference. Added state mandate footnote.\n10/2023 Annual review with no change to clinical coverage criteria. Updated\nreferences.\n10/2024 Annual review with no changes to clinical coverage criteria. Updated\nreferences.\n© 2024 UnitedHealthcare Services, Inc.\n3"
  ]
}